Passage Bio, Inc. (PASG)
Market Cap | 61.62M |
Revenue (ttm) | n/a |
Net Income (ttm) | -84.44M |
Shares Out | 61.64M |
EPS (ttm) | -1.53 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 160,707 |
Open | 0.990 |
Previous Close | 0.885 |
Day's Range | 0.990 - 1.030 |
52-Week Range | 0.575 - 1.790 |
Beta | 1.24 |
Analysts | Strong Buy |
Price Target | 9.00 (+800.36%) |
Earnings Date | Aug 5, 2024 |
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment o... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PASG stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 800.36% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/k/conf20-2463330.jpg)
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
![](https://cdn.snapi.dev/images/v1/9/u/press1-2441260.jpg)
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...
![](https://cdn.snapi.dev/images/v1/d/d/press16-2428935.jpg)
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, May 14, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...
![](https://cdn.snapi.dev/images/v1/w/z/conf9-2382633.jpg)
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
![](https://cdn.snapi.dev/images/v1/n/m/press2-2305843.jpg)
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, March 04, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases...
![](https://cdn.snapi.dev/images/v1/a/8/conf1-2295393.jpg)
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
![](https://cdn.snapi.dev/images/v1/j/n/conf16-2252720.jpg)
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
![](https://cdn.snapi.dev/images/v1/d/j/press2-2203173.jpg)
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
PHILADELPHIA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases,...
![](https://cdn.snapi.dev/images/v1/6/o/press15-2163992.jpg)
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/5/g/press10-2154145.jpg)
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/7/p/conf4-2127502.jpg)
Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/v/6/press14-2113939.jpg)
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/a/i/conf12-2075920.jpg)
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...
![](https://cdn.snapi.dev/images/v1/f/z/press10-2009454.jpg)
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/e/g/press1-2009410.jpg)
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/b/u/conf3-1998363.jpg)
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/5/w/press15-1996376.jpg)
Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/e/2/conf7-1920271.jpg)
Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/y/y/press14-1884630.jpg)
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (C...
![](https://cdn.snapi.dev/images/v1/q/q/press15-1848595.jpg)
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, April 21, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...
![](https://cdn.snapi.dev/images/v1/g/2/conf15-1839096.jpg)
Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...
![](https://cdn.snapi.dev/images/v1/t/8/conf14-1813039.jpg)
Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system ...
![](https://cdn.snapi.dev/images/v1/h/0/press1-1783146.jpg)
Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system ...
![](https://cdn.snapi.dev/images/v1/o/l/conf4-1773851.jpg)
Passage Bio to Present at Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...
![](https://cdn.snapi.dev/images/v1/9/o/conf7-1771749.jpg)
Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (...